Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Widschwendter

Showing results (111-120 of 175) with videos related to

Pageof 18
Sort By:
Oncotarget|March 25, 2014
Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver geneErling A Hoivik, Kanthida Kusonmano, Mari K Halle, et al.
The Lancet. Oncology|July 14, 2019
Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control studyNuno R Nené, Daniel Reisel, Andreas Leimbach, et al.
Clinical Epigenetics|November 22, 2022
DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN testChiara Herzog, Karin Sundström, Allison Jones, et al.
Plos One|December 3, 2015
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's CancersThomas E Bartlett, Allison Jones, Ellen L Goode, et al.
Genome Medicine|December 23, 2017
The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancerMartin Widschwendter, Michal Zikan, Benjamin Wahl, et al.
Genome Biology|February 22, 2022
Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clockJames E Barrett, Chiara Herzog, Yoo-Na Kim, et al.
Ebiomedicine|December 3, 2015
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation CarriersMartin Widschwendter, Matthew Burnell, Lindsay Fraser, et al.
The Lancet. Oncology|October 22, 2013
The sex hormone system in carriers of BRCA1/2 mutations: a case-control studyMartin Widschwendter, Adam N Rosenthal, Sue Philpott, et al.
Nature|October 1, 2010
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancerDaniel Schramek, Andreas Leibbrandt, Verena Sigl, et al.
Oncogene|September 21, 2002
Hypomethylation and hypermethylation of DNA in Wilms tumorsMelanie Ehrlich, Guanchao Jiang, Emerich Fiala, et al.
Pageof 18

Showing results (111-120 of 175) with videos related to

Sort By:
Pageof 18
Oncotarget|March 25, 2014
Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver geneErling A Hoivik, Kanthida Kusonmano, Mari K Halle, et al.
The Lancet. Oncology|July 14, 2019
Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control studyNuno R Nené, Daniel Reisel, Andreas Leimbach, et al.
Clinical Epigenetics|November 22, 2022
DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN testChiara Herzog, Karin Sundström, Allison Jones, et al.
Plos One|December 3, 2015
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's CancersThomas E Bartlett, Allison Jones, Ellen L Goode, et al.
Genome Medicine|December 23, 2017
The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancerMartin Widschwendter, Michal Zikan, Benjamin Wahl, et al.
Genome Biology|February 22, 2022
Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clockJames E Barrett, Chiara Herzog, Yoo-Na Kim, et al.
Ebiomedicine|December 3, 2015
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation CarriersMartin Widschwendter, Matthew Burnell, Lindsay Fraser, et al.
The Lancet. Oncology|October 22, 2013
The sex hormone system in carriers of BRCA1/2 mutations: a case-control studyMartin Widschwendter, Adam N Rosenthal, Sue Philpott, et al.
Nature|October 1, 2010
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancerDaniel Schramek, Andreas Leibbrandt, Verena Sigl, et al.
Oncogene|September 21, 2002
Hypomethylation and hypermethylation of DNA in Wilms tumorsMelanie Ehrlich, Guanchao Jiang, Emerich Fiala, et al.
Pageof 18